IDEXX Laboratories stock heads toward November 2 results
IDEXX Laboratories (IDXX) stock is heading towards its Q3 2026 earnings release on November 2, 2026. The company's Q2 2026 adjusted EPS of $4.27 beat the consensus of $3.94, and investors will be looking to see if this earnings conversion continues. Analysts currently have a "Moderate Buy" consensus with an average 12-month price target of $747.00, though the stock remains significantly below its 52-week high.
IDEXX Laboratories, Inc. Revenue Breakdown – XETR:IX1
IDEXX Laboratories, Inc. (IX1) generated 3.66 billion EUR in revenue last year, with its Companion Animal Group segment contributing the majority at 3.37 billion EUR. The United States was the largest regional contributor, accounting for 2.34 billion EUR. These figures highlight the company's primary revenue streams by segment and geography.
IDEXX Laboratories stock after-hours at EUR 460.50: plus 0.00 percent versus prior close
IDEXX Laboratories stock traded after-hours at EUR 460.50, unchanged from its prior close at Lang & Schwarz. The company recently acquired CoVetAI Inc., a provider of AI-native software for veterinary practices, and is set to release its Q3 2026 financial results on November 2, 2026.
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
IDEXX Laboratories, Inc. (Nasdaq: IDXX) announced it will release its 2026 third-quarter financial results on Monday, November 2, 2026, before the market opens. The company will host an analyst conference call at 8:30 a.m. ET on the same day, with a live webcast and earnings snapshot available on its investor website. An archived webcast will be accessible for one year following the call.
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
IDEXX Laboratories, Inc. (Nasdaq: IDXX) is scheduled to release its 2026 third-quarter financial results on Monday, November 2, 2026, before the market opens. The company will host an analyst conference call at 8:30 a.m. ET, which will be accessible via webcast on their investor relations website or by telephone. An archived version of the webcast will be available for one year following the live event.
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
IDEXX Laboratories, Inc. (Nasdaq: IDXX) will release its 2026 third-quarter financial results on Monday, November 2, 2026, before market open. The company will also host an analyst conference call at 8:30 a.m. ET on the same day, with a live webcast and archived version available on its investor relations website. IDEXX is a global leader in pet healthcare innovation, providing diagnostic and software products and services to veterinary practices and contributing to the safety of milk and water worldwide.
IDEXX Laboratories expands parasite testing ahead of IDEXX Laboratories stock results
IDEXX Laboratories expanded its Faecal Dx antigen testing platform in the UK to include Taeniid tapeworm detection, following its acquisition of CoVetAI. The company reported strong second-quarter 2026 revenues of $1.22 billion, up 10%, and raised its fiscal 2026 diluted EPS outlook, despite anticipated declines in veterinary office visits. IDEXX stock traded at EUR 461.05 and remains below its 52-week high.
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
Chicago Pacific Founders (CPF) has announced the exit of its investment in CoVetAI Inc. following its acquisition by IDEXX Laboratories, Inc. CoVet, a developer of an AI-powered clinical scribe platform for veterinary medicine, was a key investment for CPF's specialist animal health fund. This transaction highlights the growing role of AI in companion animal care and represents the first realization from the fund's inaugural vehicle.
IDEXX Laboratories stock after-hours at EUR 471.50: plus 1.34 percent
IDEXX Laboratories stock saw a 1.34 percent increase in after-hours trading on September 29, 2026, reaching EUR 471.50. The company recently announced the acquisition of CoVetAI Inc., an AI-based software provider for veterinary practices, and expanded its Faecal Dx antigen testing platform in the United Kingdom. This expansion now includes detection for taeniid tapeworm species at no additional cost for IDEXX Reference Laboratories customers.
IDEXX Laboratories stock gained 1.14 percent on September 25
IDEXX Laboratories stock increased by 1.14 percent on September 25, trading at USD 519.26. The company reported strong Q2 2026 revenue of USD 1,216.6 million, a 10 percent increase year over year, driven by recurring diagnostics volume. IDEXX also raised its full-year 2026 EPS guidance and completed the acquisition of CoVetAI to enhance its software ecosystem.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock price increase by 1.89% to $529.06 on Monday, outperforming the broader market. This gain occurred despite a general downturn in the stock market, with both the S&P 500 Index and Dow Jones Industrial Average experiencing declines. This marks the second consecutive day of gains for IDEXX stock.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) stock increased by 1.14% on Friday, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average. The company's shares closed at $519.26, still 32.56% below its 52-week high.
IDEXX Laboratories stock heads into the open after September 24 update
IDEXX Laboratories stock's performance on September 24, 2026, is detailed, noting its close relative to the Nasdaq Composite. The article also highlights IDEXX's expansion of its Fecal Dx antigen test in Germany and provides market context for September 24th and the outlook for September 25th.
IDEXX Laboratories Inc. stock underperforms Thursday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock decreased by 1.65% on Thursday, closing at $513.39. This underperformance occurred during a generally negative trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average also experiencing slight declines. The stock's fall ended a four-day winning streak.
IDEXX Laboratories, Inc. (IDXX) stock price, news, quote and history
This article provides a comprehensive overview of IDEXX Laboratories, Inc. (IDXX) stock, including its current price, historical data, financial performance, and analyst insights. It details the company's operations across companion animal, water quality, and livestock segments, highlighting its diverse product and service offerings in diagnostics and research. The report also includes key financial metrics, performance comparisons against the S&P 500, and analysts' price targets.
Labcorp Holdings Inc. (LH) stock price, news, quote and history
This Yahoo Finance page provides comprehensive information on Labcorp Holdings Inc. (LH), including its current stock price, financial statistics, historical data, and recent news. The company, a diagnostics and research healthcare provider, offers various laboratory services and has recently highlighted strategic priorities for growth and shareholder value. The article also includes performance comparisons against the S&P 500 and analyst insights, with Truist Securities maintaining a "Buy" rating and raising the price target to $365.
Should You Continue to Hold IDXX Stock in Your Portfolio?
IDEXX Laboratories (IDXX) is strengthening its Companion Animal Group (CAG) business through increased recurring revenue, wider customer adoption, and expanding diagnostic offerings, with strong international performance. However, foreign exchange headwinds and a continued decline in U.S. veterinary clinical visits are restraining its full growth potential. Despite these challenges, the company's earnings have consistently surpassed estimates.
IDEXX Laboratories stock heads into the open after a 1.16 percent gain
IDEXX Laboratories (IDXX) stock closed at USD 517.57 on Nasdaq on September 21, 2026, marking a 1.16 percent gain. A snapshot from September 22, 2026, showed the stock at USD 522.81 with 508,758 shares traded, placing it above its 52-week low but below its 52-week high. The Nasdaq Composite also saw a 0.45 percent gain, closing at 27,244.28, driven by technology and AI shares.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock rise by 1.20% to $521.50 on Tuesday, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average experienced a slight decline.
IDEXX Laboratories stock gains 1.16 percent as valuation holds
IDEXX Laboratories stock gained 1.16 percent, closing at USD 517.57 on September 21, 2026, with market capitalization at USD 40.60 billion. Despite this gain, the stock remains significantly below its 52-week high, although above its yearly low. The company's valuation is supported by projected revenue growth of 7.0 percent for 2026 and strong earnings, but a high price-to-earnings ratio and insider selling introduce technical risk.
Recent acquisitions: IDEXX buys CoVet, The Farmer's Dog acquires Woof
Two significant acquisitions recently closed in the pet industry, signaling continued growth and investment. IDEXX Laboratories acquired CoVetAI Inc., a provider of AI-powered clinical documentation software for veterinary practices, to enhance its software ecosystem and clinical decision support. Separately, The Farmer's Dog, a fresh dog food company, completed its first acquisition by purchasing Woof, a pet wellness brand known for its refillable enrichment products like the Pupsicle, which will continue to operate independently.
IDEXX Laboratories Inc | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a notice regarding the proposed sale of securities of IDEXX Laboratories Inc. The notice is filed pursuant to Rule 144 of the Securities Act, indicating an upcoming transaction involving restricted or control securities.
IDEXX Laboratories stock holds after Stifel keeps Buy rating
Stifel maintained a Buy rating on IDEXX Laboratories (IDXX) stock with a USD 675 target, despite the shares trading significantly below this target and near a 52-week low. The company's Q2 2026 adjusted EPS and revenue surpassed consensus estimates, driven by strong recurring diagnostics revenue. However, the stock's current valuation near its annual floor and the analyst's price target gap are key considerations for investors.
Illumina Names Chief Commercial Officer and Chief Legal Officer
Illumina Inc. has appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer. These new hires bring extensive leadership experience from the life sciences, diagnostics, and medical technology sectors, aiming to strengthen Illumina's executive team and drive continued growth and customer service.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) shares rallied 1.02% to $511.65 on Friday, outperforming the S&P 500 Index which rose 0.17% and the Dow Jones Industrial Average which fell 0.18%. Despite the gain, the stock remains 33.55% below its 52-week high.
IDEXX Stock Gains Following the Acquisition of CoVet
IDEXX Laboratories, Inc. (IDXX) announced the acquisition of CoVetAI Inc., a provider of AI-native ambient listening and clinical workflow software for veterinary practices. This acquisition is expected to enhance IDEXX's software ecosystem and diagnostic capabilities, integrating AI to improve workflow efficiency and practice performance. The stock saw a slight gain following the announcement, reflecting positive market sentiment and the company's strategic focus on AI and software integration in the growing veterinary AI diagnostics market.
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
IDEXX Laboratories, Inc. has expanded its Faecal Dx antigen testing platform in the United Kingdom to include detection of taeniid tapeworms, such as Taenia and Echinococcus species. This expansion allows for broader parasite detection, identifying up to twice as many intestinal parasite infections earlier than traditional faecal flotation. The enhanced platform now covers seven clinically relevant intestinal parasite groups, providing more comprehensive diagnostic capabilities for veterinary professionals.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Laboratories has acquired CoVetAI, a provider of AI-native ambient listening and clinical workflow software for veterinary practices. This acquisition aims to enhance IDEXX's software, diagnostics, and AI offerings by making information more accessible and connected across the practice. CoVet's technology helps reduce documentation burden for veterinary teams, allowing them to focus more on patient care, and will integrate with IDEXX's existing ecosystem while continuing to support third-party systems.
IDEXX Stock Gains Following the Acquisition of CoVet
IDEXX Laboratories recently acquired CoVetAI Inc., a company specializing in AI-native clinical workflow software for veterinary practices, to enhance diagnostic insights and practice efficiency. This acquisition is expected to boost positive market sentiment for IDEXX, which has a strong market capitalization and favorable earnings yield compared to its industry. The integration of CoVet into IDEXX's software ecosystem aims to improve practice workflows, deepen integration of patient information, and increase diagnostic utilization in a growing global veterinary AI diagnostics market.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Laboratories, a leader in pet healthcare innovation, has acquired CoVetAI Inc., a company specializing in AI-native ambient listening and clinical workflow software for veterinary practices. This acquisition aims to enhance efficiency, clinical decision-making, and diagnostic utilization by integrating CoVet's technology into IDEXX's existing software ecosystem. The move strengthens IDEXX's commitment to leveraging AI to improve veterinary workflow and patient care globally.
Press Release: IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
IDEXX Laboratories has acquired CoVetAI, a company specializing in artificial intelligence solutions for veterinary practices. This acquisition aims to enhance IDEXX's offerings by integrating CoVetAI's workflow intelligence technology, which is designed to improve operational efficiency and patient care in veterinary hospitals. The move is part of IDEXX's strategy to advance veterinary diagnostics and information management through innovative AI applications.
Engaging In Options Activity, Lawrence D Kingsley Exercises Options Valued At $873K In IDEXX Laboratories
Lawrence D Kingsley, a Board Member at IDEXX Laboratories (NASDAQ: IDXX), recently exercised stock options for 2,203 shares, valued at $873,225, as revealed in a September 9 SEC filing. The article highlights IDEXX Laboratories' strong financial performance with impressive revenue growth, high gross margins, and a notable EPS, though it notes a higher-than-average debt-to-equity ratio and premium valuations. This insider transaction provides insight into company confidence but should be considered alongside comprehensive financial analysis.
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
IDEXX Laboratories Director Lawrence D. Kingsley sold 2,203 shares of stock worth $1.2 million on September 4, 2026, after exercising options. Despite the sale, Kingsley retains a significant stake of 9,568 shares valued at $5.12 million, indicating continued confidence in the company. The article notes that this exercise-and-sell transaction is typical for insiders and that IDEXX continues to demonstrate strong financial performance with double-digit growth in sales and EPS.
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock
IDEXX Laboratories Director Lawrence D. Kingsley sold 2,203 shares of company stock worth $1.2 million on September 4, 2026, through an exercise-and-sell transaction. Despite the sale, Kingsley retains a significant holding of over $5 million in IDXX stock. The article emphasizes that this is a typical insider transaction and highlights IDEXX's strong financial performance, double-digit growth, and more reasonable valuation after a 30% stock drop, making it an attractive investment according to the author.
Is IDEXX Laboratories Stock Underperforming the Dow?
IDEXX Laboratories (IDXX) stock has significantly underperformed the Dow Jones Industrial Average over the past year and in 2026, with shares down 23.9% year-to-date and 21.4% over 52 weeks, compared to the Dow's positive returns. Despite this, the company showed improving momentum in Q2, with strong revenue and EPS growth, and analysts maintain a "Moderate Buy" rating with a substantial price target premium. The underperformance is attributed to investor concerns about slower veterinary clinic traffic, though recent results suggest a recovery.
Idexx Laboratories stock hits 52-week low at $517.00 By Investing.com
Idexx Laboratories Inc. (IDXX) stock has hit a 52-week low of $517.00, despite the company reporting strong second-quarter earnings that surpassed analyst expectations. The company saw increased demand for diagnostics and improved margins, leading management to raise its full-year guidance. Stifel has reiterated a buy rating with a $675 price target, highlighting the company's market share capture and strong long-term fundamentals.
Idexx Laboratories stock hits 52-week low at $517.00 By Investing.com
Idexx Laboratories (IDXX) stock hit a 52-week low of $517.00, though InvestingPro analysis suggests it is undervalued. Despite an 18.46% decline over the past year, the company boasts strong financial health with a perfect Piotroski Score of 9 and management's aggressive share buybacks. Recent news also highlights strong second-quarter earnings that surpassed expectations and a reiterated "buy" rating from Stifel, indicating robust performance and market positioning.
Idexx Laboratories stock hits 52-week low at $517.00
Idexx Laboratories (IDXX) stock has hit a 52-week low of $517.00, despite an InvestingPro analysis suggesting it is undervalued. The company reported strong second-quarter earnings, exceeding analyst expectations, and management has raised its full-year guidance. Stifel reiterated a buy rating with a $675 price target, highlighting IDEXX's strong fundamentals and market share gains.
IDEXX Laboratories stock heads into the open after a modest gain
IDEXX Laboratories stock closed slightly higher on the Nasdaq on September 8, 2026, gaining 0.8% to USD 232.40, outperforming the S&P 500 which slipped 0.4%. The company had no specific news, but investors are watching upcoming CPI and PPI inflation data and broader market sentiment remains fragile due to rising oil prices and geopolitical tensions.
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
IDEXX Laboratories Inc. (IDXX) stock declined 2.83% on Tuesday, closing at $520.21, amidst a general downturn in the stock market where the S&P 500 and Dow Jones also fell. The company's shares are now 32.44% below their 52-week high of $769.98, achieved on November 26th. This performance indicates IDEXX underperformed relative to its competitors and broader market indices.
ETFs Investing in IDEXX Laboratories, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of IDEXX Laboratories, Inc. (IDXX). It provides a detailed table including each fund's market value, weight of IDEXX stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, and 3-year NAV total return. The ETFs cover different market segments such as total market, large-cap, mid-cap, and specific sectors like health care and water resources.
Precipio Inc (NASDAQ: PRPO) Share Price, PRPO Stock News, PRPO Share Price & Updates
This article provides a comprehensive overview of Precipio Inc. (NASDAQ: PRPO), a healthcare solutions company specializing in diagnostic products and services for blood cancer. It details the company's current stock price, key financial metrics, historical income statement and balance sheet data, and a peer comparison with other diagnostics and research firms. The profile highlights Precipio's offerings, including IV-Cell and HemeScreen, and lists its corporate contact information and key personnel.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) saw its stock rise by 1.15% to $535.38 on Friday, despite an overall negative trading day for the broader market. This performance allowed IDEXX to outperform the S&P 500 Index and the Dow Jones Industrial Average, both of which experienced declines. The increase ended a three-day losing streak for the company's stock.
Resilient IDEXX Laboratories stock holds above $550 as earnings beat supports guidance
IDEXX Laboratories (IDXX) stock is trading resiliently above $550, supported by strong Q2 2026 earnings, which saw EPS of $4.27 and revenue of $1.22 billion, both exceeding analyst estimates. The company reaffirmed its full-year 2026 EPS guidance in the mid-teens, aligning with analyst consensus and reflecting continued growth in its veterinary diagnostics and animal health solutions. Institutional investors are increasing holdings, and the long-term performance history demonstrates significant value creation, despite the stock trading near its twelve-month low.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, Inc. announced that its President and CEO, Mike Erickson, and Executive Vice President and CFO, Andrew Emerson, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for September 14, 2026, and a live audio webcast will be available on the IDEXX investor relations website. IDEXX is a global leader in pet healthcare innovation, providing diagnostic and software products and services to the veterinary community.
Resilient IDEXX Laboratories stock trades above $550 as growth outlook stays strong
IDEXX Laboratories stock is trading above $550, driven by a strong growth outlook, including an anticipated 13.2% year-over-year earnings growth for the current fiscal year, and positive analyst sentiment. Six analysts have raised their earnings estimates for fiscal 2026, pushing the consensus EPS to $14.81. Despite a premium valuation, analysts maintain a "Moderate Buy" rating with an average price target of $747.00, indicating significant potential upside.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, Inc. (Nasdaq: IDXX) announced that its President and CEO, Mike Erickson, and Executive Vice President and CFO, Andrew Emerson, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for Monday, September 14, 2026, from 10:45 am – 11:20 am ET, and a live audio webcast will be available on the IDEXX investor relations website.
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, Inc. announced that its President and CEO, Mike Erickson, and Executive Vice President and CFO, Andrew Emerson, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The event is scheduled for Monday, September 14, 2026, from 10:45 am – 11:20 am (ET), and a live audio webcast will be available on the IDEXX website. IDEXX is a global leader in pet healthcare innovation, providing diagnostic and software products and services to the veterinary community and contributing to the safety of milk and water worldwide.
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day
IDEXX Laboratories Inc. (IDXX) shares rallied 1.82% to $554.99 on Friday, outperforming the broader market as both the S&P 500 and Dow Jones Industrial Average experienced declines. The company's stock closed 27.92% below its 52-week high. This performance occurred despite a generally tough trading session for the stock market.
IDEXX Laboratories Inc. (IDXX) Key Financial Ratios – Valuation, Profitability & More
This article provides a detailed analysis of IDEXX Laboratories Inc. (IDXX) through its key financial ratios, covering valuation, profitability, growth, solvency, and operating efficiency. It presents TTM data alongside yearly figures and compares IDEXX's performance against peer medians across various metrics like ROE, EBIT Margin, Revenue Growth, and Debt to Equity. The analysis highlights IDEXX's strengths in profitability and growth compared to its peers.
